Suppr超能文献

基于智能手机视频观察治疗与社区直接观察治疗的肺结核治疗依从性:一项整群随机对照试验的方案

Tuberculosis Treatment Compliance Under Smartphone-Based Video-Observed Therapy Versus Community-Based Directly Observed Therapy: Protocol for a Cluster Randomized Controlled Trial.

作者信息

Kumwichar Ponlagrit, Chongsuvivatwong Virasakdi, Prappre Tagoon

机构信息

Epidemiology Department, Faculty of Medicine, Prince of Songkla University, Hat Yai District, Thailand.

出版信息

JMIR Res Protoc. 2022 Jul 8;11(7):e38796. doi: 10.2196/38796.

Abstract

BACKGROUND

The health care system in Thailand has struggled to cope with the COVID-19 pandemic, resulting in decreased administration of community-based directly observed therapy (DOT) for tuberculosis (TB). As an alternative to failed DOT, video-observed therapy (VOT) or the Thai asynchronous VOT system, "TH VOT," was devised. We developed a protocol for a study to test the superiority of VOT over DOT in ensuring treatment compliance.

OBJECTIVE

We aim to compare the mean cumulative compliance days of TB patients and their observers under the VOT program with that of individuals under the DOT program during the intensive phase of TB treatment.

METHODS

A cluster randomized controlled trial of pulmonary TB patients and their observers will be conducted over a 2-month period. This study will be conducted in the Hat Yai and Meuang Songkhla districts of Songkhla Province, Southern Thailand. A total of 38 observers working at 38 primary care units (PCUs) will be randomized equally into VOT and DOT groups. The TH VOT system will be implemented in 19 PCUs in the VOT group while the other 19 PCUs will continue with the traditional DOT program. Approximately 1-5 TB patients will be under observation, depending on the PCU jurisdiction in which the patients reside. The inclusion criteria for TB patients will be as follows: patients diagnosed with newly active pulmonary TB with a positive acid-fast bacilli sputum smear, aged >18 years, own a smartphone, and are able to use the LINE (Line Corporation) app. The exclusion criteria will be patients with a condition that requires the intervention of a specialist, rifampicin resistance according to a cartridge-based nucleic acid amplification test (GeneXpert MTB/RIF), unable to continue the treatment, and/or alcohol dependence. After the 2-month observation period, all sessions and follow-up clinical outcomes recorded will be retrieved. An intention-to-treat analysis will be performed to assess the compliance of both patients undergoing drug administration and their observers.

RESULTS

The Human Research Ethics Committee, Faculty of Medicine, Prince of Songkla University approved the trial on February 19, 2021 (approval number 64-03618-9). The trial was funded in May 2021. The recruitment period will be from January 2022 to July 2022. The observation is scheduled to end by September 2022.

CONCLUSIONS

If the VOT shows superiority in observational compliance among patients and observers, the existing DOT policy will be replaced with VOT.

TRIAL REGISTRATION

Thai Clinical Trials Registry TCTR20210624002; https://www.thaiclinicaltrials.org/show/TCTR20210624002.

INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/38796.

摘要

背景

泰国的医疗保健系统一直在努力应对新冠疫情,导致基于社区的结核病直接观察治疗(DOT)的实施减少。作为失败的DOT的替代方案,设计了视频观察治疗(VOT)或泰国异步VOT系统“TH VOT”。我们制定了一项研究方案,以测试VOT在确保治疗依从性方面优于DOT。

目的

我们旨在比较结核病患者及其观察者在VOT计划下与DOT计划下的患者在结核病强化治疗阶段的平均累积依从天数。

方法

将对肺结核患者及其观察者进行为期2个月的整群随机对照试验。本研究将在泰国南部宋卡府的合艾和宋卡直辖县进行。在38个基层医疗单位(PCU)工作的38名观察者将被平均随机分为VOT组和DOT组。VOT组的19个PCU将实施TH VOT系统,而其他19个PCU将继续采用传统的DOT计划。根据患者居住的PCU管辖范围,大约1 - 5名结核病患者将接受观察。结核病患者的纳入标准如下:新诊断为活动性肺结核且痰涂片抗酸杆菌阳性、年龄>18岁、拥有智能手机且能够使用LINE(Line Corporation)应用程序。排除标准将为需要专科干预的患者、根据基于 cartridge 的核酸扩增试验(GeneXpert MTB/RIF)显示利福平耐药、无法继续治疗和/或酒精依赖的患者。在2个月的观察期结束后,将检索记录的所有疗程和后续临床结果。将进行意向性分析,以评估接受药物治疗的患者及其观察者的依从性。

结果

宋卡王子大学医学院人类研究伦理委员会于2021年2月19日批准了该试验(批准号64 - 03618 - 9)。该试验于2021年5月获得资助。招募期为2022年1月至2022年7月。观察计划于2022年9月结束。

结论

如果VOT在患者和观察者的观察依从性方面显示出优越性,现有的DOT政策将被VOT取代。

试验注册

泰国临床试验注册中心TCTR20210624002;https://www.thaiclinicaltrials.org/show/TCTR20210624002。

国际注册报告识别码(IRRID):DERR1 - 10.2196/38796。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/003f/9308080/19757a9360ba/resprot_v11i7e38796_fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验